PT  - JOURNAL ARTICLE
AU  - Lewis, Dana M.
AU  - Leibrand, Scott
AU  - Leibrand, Howard
TI  - A Test-Based Strategy for Safely Shortening Quarantine for COVID-19
AID  - 10.1101/2020.11.24.20238287
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.11.24.20238287
4099  - http://medrxiv.org/content/early/2020/11/29/2020.11.24.20238287.short
4100  - http://medrxiv.org/content/early/2020/11/29/2020.11.24.20238287.full
AB  - Quarantine for COVID-19 is hard and could safely be made easier. Lengthy quarantine is difficult for many individuals to rigorously observe. To date, 14 days has been recommended as the quarantine period for people who are exposed to a confirmed COVID-19 case, because most infections appear by then. For household close contacts, there remains a 0.5% chance that a COVID-19 infection may appear after that time, because the COVID-19 incubation period is up to 21 days. However, the risk of transmission after 14 days is so small that public health authorities have decided that 0.5% is an acceptable risk to balance the impact of quarantine on individuals, their communities, and our economy. Therefore, this 0.5% risk of infection is a useful benchmark to consider additional strategies for reducing the burden on individuals while reducing spread of COVID-19. With appropriately timed testing and awareness of possible symptoms, a non-symptomatic individual with a negative COVID-19 test at day 7-8 would be at lower risk of being or becoming infectious than someone completing a 14-day quarantine without testing. If we implemented a test-based strategy for determining the end of quarantine, these individuals could be safely released from quarantine at an earlier date, and would be able to more rigorously quarantine themselves while potentially most infectious.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:n/aAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from the calculations is available in the supplementary files, and a spreadsheet with this calculated data is available: https://bit.ly/TestBasedCOVID19QuarantineData